Crinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new non-executive employees.

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences


Crinetics management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference.

Crinetics Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees.

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update


Crinetics Pharmaceuticals reported second quarter 2024 financial and provided a business update on clinical progress.

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges


Crinetics launches ACRO/TRUTH, a website and educational initiative aimed at highlighting the various acromegaly treatment challenges.